Phase II study of high dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis - JCOG study 9413

被引：22
|
作者：
Sekine, I
Nishiwaki, Y
Kakinuma, R
Kubota, K
Hojo, F
Matsumoto, T
Ohmatsu, H
Yokozaki, M
Goto, K
Miyamoto, T
Takafuji, J
Kodama, T
机构：
[1] Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa-city, Chiba 277
来源：
BRITISH JOURNAL OF CANCER | 1997年 / 76卷 / 01期
关键词：
delayed emesis; cisplatin; chemotherapy; high-dose dexamethasone; lung cancer;
D O I：
10.1038/bjc.1997.341
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Thirty-three patients with lung cancer receiving 80 mg m(-2) cisplatin were treated with high-dose dexamethasone (32 mg m(-2) on days 1-3, 16 mg m(-2) on day 4 and 8 mg m(-2) on day 5) combined with granisetron on day 1 and metoclopramide on days 2-5. Twenty-eight (85%) patients had no nausea or vomiting on day 1, and 16 (48%) achieved total control on days 1-5 with acceptable toxicity. High-dose dexamethasone for cisplatin-induced delayed emesis should be further evaluated in a phase III trial.
引用
收藏
页码：90 / 92
页数：3
相关论文
共 50 条
  • [1] Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis – JCOG study 9413
    I Sekine
    Y Nishiwaki
    R Kakinuma
    K Kubota
    F Hojo
    T Matsumoto
    H Ohmatsu
    M Yokozaki
    K Goto
    T Miyamoto
    J Takafuji
    T Kodama
    British Journal of Cancer, 1997, 76 : 90 - 92
  • [2] Total control of cisplatin-induced delayed emesis with high-dose dexamethasone - Japan Clinical Oncology Group (JCOG) study 9413
    Sekine, I
    Nishiwaki, Y
    Kakinuma, R
    Kubota, K
    Hojo, F
    Matsumoto, T
    Ohmatsu, H
    Yokozaki, M
    Goto, K
    Miyamoto, T
    Ttakafuji, J
    10TH MEDITERRANEAN CONGRESS OF CHEMOTHERAPY, 1996, : 611 - 615
  • [3] HIGH-DOSE DEXAMETHASONE AND HIGH-DOSE METOCLOPRAMIDE VERSUS HIGH-DOSE DEXAMETHASONE AND SULPIRIDE IN THE MANAGEMENT OF CISPLATIN-INDUCED EMESIS
    ROSENBLATT, E
    LEV, LM
    ROBINSON, E
    ONCOLOGY, 1988, 45 (04) : 297 - 299
  • [4] ONDANSETRON PLUS DEXAMETHASONE IN THE CONTROL OF HIGH-DOSE CISPLATIN-INDUCED EMESIS
    MAISANO, R
    TOSCANO, G
    ADAMO, V
    ALTAVILLA, G
    CARISTI, N
    CHIOFALO, G
    GNANI, A
    SCIMONE, A
    JOURNAL OF CHEMOTHERAPY, 1993, 5 (01) : 60 - 62
  • [5] THE CONTROL OF ACUTE CISPLATIN-INDUCED EMESIS - A COMPARATIVE-STUDY OF GRANISETRON AND A COMBINATION REGIMEN OF HIGH-DOSE METOCLOPRAMIDE AND DEXAMETHASONE
    CHEVALLIER, B
    BRITISH JOURNAL OF CANCER, 1993, 68 (01) : 176 - 180
  • [6] HIGH-DOSE METOCLOPRAMIDE AND CHLORPROMAZINE IN THE TREATMENT OF CISPLATIN-INDUCED EMESIS
    AASEBO, U
    SLORDAL, L
    PRYTZ, PS
    AARBAKKE, J
    PHARMACOLOGY & TOXICOLOGY, 1987, 60 (05): : 337 - 339
  • [7] HIGH-DOSE DEXAMETHASONE FOR PREVENTION OF CISPLATIN-INDUCED VOMITING
    AAPRO, MS
    ALBERTS, DS
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1981, 7 (01) : 11 - 14
  • [8] THE BENEFIT AND RISK OF HIGH-DOSE METOCLOPRAMIDE IN COMPARISON TO HIGH-DOSE HALOPERIDOL OR TRIFLUPROMAZINE IN CISPLATIN-INDUCED EMESIS
    SALLER, R
    HELLENBRECHT, D
    KLINISCHE WOCHENSCHRIFT, 1985, 63 (09): : 428 - 432
  • [9] Granisetron plus methylprednisolone for the control of high-dose cisplatin-induced emesis
    Kleisbauer, JP
    Garcia-Giron, C
    Antimi, M
    Azevedo, MC
    Balmes, H
    Massuti-Sureda, B
    Contu, A
    Luque, A
    Pellier, P
    ANTI-CANCER DRUGS, 1998, 9 (05) : 387 - 392
  • [10] PHARMACOKINETICS OF HIGH-DOSE IV ALIZAPRIDE IN PREVENTION OF CISPLATIN-INDUCED EMESIS
    CANAL, P
    ROCHE, H
    PASQUIER, M
    BUGAT, R
    BERG, D
    SOULA, G
    CARTON, M
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1987, 1 (03) : 213 - 217
12345